UAB 1761: A Randomized, Placebo-Controlled, Double-Blind, Phase II trial of Nanoparticle Albumin-Bound Paclilaxel (Nab-Paclilaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple Negative Breast Cancer.

Grant

Date/time Interval

  • December 8, 2017 - July 31, 2021

    • Awarded By

    Total Award Amount

  • 102500.00

    • Direct Costs

  • 78846.00

    • Sponsor Award Id

    • Contributor

  • Erica Stringer-Reasor M.D.   Principal Investigator  
  • Gabrielle Rocque M.D.   Investigator